Schering May Cough Up Hefty Payment to FDA

Pfizer to pay $43 million to settle Rezulin suit; Quaker Chemical sees lower earnings; plus more of today's stocks to watch

Schering-Plough (SGP ) says it may have to pay up to $500 million to resolve manufacturing issues with the U.S. Food and Drug Administration. The company received FDA approval for its Clarinex antihistamine. Schering sees fourth-quarter EPS from operations about 7% below one year ago, and 2002 EPS growth in the low double-digits. Goldman cut its estimates on Schering.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.